Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

689 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-05-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers for lung cancer using tissue samples from patients with lung cancer and from healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

NCT00899457

Healthy, no Evidence of Disease Lung Cancer

COMPLETED

Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01139944

Lung Cancer

COMPLETED

Detection of Genetic Markers of Lung Cancer

NCT00280202

Lung Cancer

RECRUITING

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595

Lung Cancer

COMPLETED

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281

Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung.
* To determine the prevalence of candidate biomarkers in lung cancer progression.
* To determine the odds of developing lung cancer according to biomarker status in preinvasive lesions.
* To determine the odds of developing lung cancer according to proteomic biomarker status in the normal bronchial epithelium of high-risk patients.

OUTLINE: This is a multicenter study.

Tissue samples are collected at the time of fluorescence bronchoscopy for laboratory biomarker studies. Blood, sputum, and urine samples are also collected. Gene and protein expression studies are performed on the samples using comparative genomic hybridization array, 3q oligonucleotide microarray, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC).

Patients' medical records are reviewed to collect information about the patient's past medical history and pertinent laboratory and radiography results.

Patients and healthy volunteers are followed annually via telephone or a mailed questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

comparative genomic hybridization

Intervention Type GENETIC

fluorescence in situ hybridization

Intervention Type GENETIC

gene expression analysis

Intervention Type GENETIC

microarray analysis

Intervention Type GENETIC

protein expression analysis

Intervention Type GENETIC

immunohistochemistry staining method

Intervention Type OTHER

laboratory biomarker analysis

Intervention Type OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

Intervention Type OTHER

medical chart review

Intervention Type OTHER

diagnostic bronchoscopy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Meets 1 of the following criteria:

* Known or previously diagnosed lung cancer
* Suspected lung cancer, including the following:

* Completely resected stage I lung cancer (with no evidence of metastatic disease) for which patient is at risk for developing secondary disease
* Suspected of having lung cancer due to clinical symptoms, such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough, and positive x-ray
* Healthy volunteer

PATIENT CHARACTERISTICS:

* WBC ≥ 2,000/mm³ but ≤ 20,000/mm³
* Platelet count ≥ 50,000/mm³
* Not pregnant
* No uncontrolled hypertension (i.e., systolic blood pressure \> 200 mm Hg, diastolic blood pressure \> 120 mm Hg)
* No unstable angina
* No known bleeding disorder
* No other contraindications for white light bronchoscopic examination
* No other contraindications for fluorescence examination

PRIOR CONCURRENT THERAPY:

* More than 3 months since prior fluorescent photosensitizing agents (hematoporphyrin derivatives)
* More than 3 months since prior and no concurrent chemopreventative drugs (e.g., tretinoin)
* More than 6 months since prior ionizing radiation treatment to the chest
* More than 6 months since prior systemic cytotoxic chemotherapy
* No concurrent anticoagulant therapy

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes